TrialBMC cancer2016

DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma.

Thomas J Ettrich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.